Lyell Immunopharma, Inc. (LYEL) vs Sutro Biopharma, Inc. (STRO)
Lyell Immunopharma, Inc. and Sutro Biopharma, Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. and Sutro Biopharma, Inc. are of similar size ($260.5M and $248.0M). Lyell Immunopharma, Inc. grew revenue faster over the last twelve months: −55.0% against −56.3%. Sutro Biopharma, Inc. has the higher net margin (−395.3% vs −920,285.2%) and the higher return on invested capital (0.00% vs −539.5%). Across the 15 metrics below, Sutro Biopharma, Inc. leads on 11 and Lyell Immunopharma, Inc. on 4.
Valuation
Profitability
| Metric | LYEL | STRO | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (949,981.48%) | (319.57%) | 0.00% |
| Net margin | (920,285.19%) | (395.25%) | 0.00% |
| Free cash flow margin | (647,681.48%) | (318.63%) | 0.00% |
| Return on equity | (93.28%) | 266.76% | (57.72%) |
| Return on assets | (71.34%) | (79.08%) | (49.22%) |
| Return on invested capital | (539.53%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack